Cargando…
Thyromimetics: What does the future hold?
Thyromimetic agents that can treat dyslipidemia without adverse effects like cardiac arrhythmias and osteoporosis are attractive options. Initial experience with desssicated thyroid hormone extract and DT4 were disappointing. Thyroid hormone has nuclear action with four receptor isoforms- TR α1, TRα...
Autores principales: | Unnikrishnan, A. G., Baruah, Manash, Kalra, Sanjay |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603016/ https://www.ncbi.nlm.nih.gov/pubmed/23565368 http://dx.doi.org/10.4103/2230-8210.104029 |
Ejemplares similares
-
What the future holds for gliptins
por: Jindal, Radhika, et al.
Publicado: (2012) -
Sub-clinical addison's disease
por: Baruah, Manash P.
Publicado: (2012) -
Degludec insulin: A novel basal insulin
por: Kalra, Sanjay, et al.
Publicado: (2011) -
What does the future hold?
por: de Campos, Fernando Peixoto Ferraz
Publicado: (2012) -
Diabetic nephropathy: What does the future hold?
por: Montero, R. M., et al.
Publicado: (2015)